IVC Wealth Advisors LLC Grows Stock Position in Eli Lilly and Company (NYSE:LLY)

IVC Wealth Advisors LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.1% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,434 shares of the company’s stock after acquiring an additional 16 shares during the period. IVC Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,184,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Knightsbridge Asset Management LLC grew its holdings in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock worth $628,000 after purchasing an additional 15 shares during the period. Centerpoint Advisory Group purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $514,000. Kentucky Trust Co acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $834,000. CSM Advisors LLC lifted its position in Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock valued at $807,000 after buying an additional 245 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in Eli Lilly and Company by 30.2% during the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company’s stock worth $5,202,000 after buying an additional 1,562 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Truist Financial upped their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Finally, HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,011.37.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 2.2%

Shares of Eli Lilly and Company stock opened at $738.33 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a market capitalization of $699.74 billion, a P/E ratio of 63.05, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a 50 day moving average of $776.85 and a 200 day moving average of $799.96.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Eli Lilly and Company’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.58 earnings per share. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.